These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 22287733)
21. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells. Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150 [TBL] [Abstract][Full Text] [Related]
22. NVP-BEZ235 as a new therapeutic option for sarcomas. Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094 [TBL] [Abstract][Full Text] [Related]
23. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy. Hernlund E; Olofsson MH; Fayad W; Fryknäs M; Lesiak-Mieczkowska K; Zhang X; Brnjic S; Schmidt V; D'Arcy P; Sjöblom T; De Milito A; Larsson R; Linder S Eur J Cancer; 2012 Feb; 48(3):396-406. PubMed ID: 22154651 [TBL] [Abstract][Full Text] [Related]
24. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Schnell CR; Stauffer F; Allegrini PR; O'Reilly T; McSheehy PM; Dartois C; Stumm M; Cozens R; Littlewood-Evans A; García-Echeverría C; Maira SM Cancer Res; 2008 Aug; 68(16):6598-607. PubMed ID: 18701483 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532 [TBL] [Abstract][Full Text] [Related]
26. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668 [TBL] [Abstract][Full Text] [Related]
27. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026 [TBL] [Abstract][Full Text] [Related]
28. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325 [TBL] [Abstract][Full Text] [Related]
29. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger S; Flentje M; Djuzenova CS Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Li H; Jin X; Zhang Z; Xing Y; Kong X Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777 [TBL] [Abstract][Full Text] [Related]
31. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model. Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317 [TBL] [Abstract][Full Text] [Related]
32. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799 [TBL] [Abstract][Full Text] [Related]
33. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826 [TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354 [TBL] [Abstract][Full Text] [Related]
35. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1. Lin G; Gai R; Chen Z; Wang Y; Liao S; Dong R; Zhu H; Gu Y; He Q; Yang B Eur J Pharmacol; 2014 Apr; 729():45-53. PubMed ID: 24561043 [TBL] [Abstract][Full Text] [Related]
36. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698 [TBL] [Abstract][Full Text] [Related]
37. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720 [TBL] [Abstract][Full Text] [Related]
38. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia. Wong J; Welschinger R; Hewson J; Bradstock KF; Bendall LJ Oncotarget; 2014 Nov; 5(21):10460-72. PubMed ID: 25361005 [TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary. Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]